Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Samsung Medical Center
With
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven non-small cell lung cancer
Presence of measurable disease by RECIST
Inoperable Stage IIIA or IIIB, proven by CT or MRI (except wet T4). However, N2 or N3 should be confirmed by PET or pathology. (For T4, PET is optional)
18 years of age or older
ECOG Performance status 0-1
No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
Serum creatinine ≤1.25 x UNL or creatinine clearance ≥60 mlmL/min
Serum bilirubin ≤ 1.5 x UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL, alkaline phosphatase ≤ 5 x UNL
FEV1\> 0.8 L
Patients must sign an informed consent
You may not be if
Carcinoid tumor, small cell carcinoma of lung
Patients with any distant metastasis
History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
Any other morbidity or situation with contraindication for chemotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment)
Pregnant or lactating women, women who has not taken test of pregnancy (within 14 days before the first administration) and pregnant women
Women and men of childbearing potential who have no willing of employing adequate contraception
Clareo Health | Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
